BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Chong Kun Dang's anemia biosimilar wins regulatory approval at home

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : December 3, 2018, 10:13 | Updated : December 3, 2018, 10:13
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Chong Kun Dang]



SEOUL -- CKD-11101, a biosimilar developed by South Korea's pharmaceutical company Chong Kun Dang has won regulatory approval at home to sell the world's first copycat of Nesp for the treatment of anemia of chronic disease associated with cancer.

Chong Kun Dang said the Ministry of Food and Drug Safety has approved CKD-11101. Marketing is possible in South Korea next year. It is the world's first biosimilar referencing Nesp codeveloped by Japan’s Kyowa Hakko Kirin and Amgen.

Through a partnership with a multinational company, Chong Kun Dang's biosimilar has filed for approval in Japan. The company has patented CKD-11101 in Europe and the United States to accelerate global sales.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Samsung Bioepis forges licensing deal with Chinese private equity firm .
    Samsung Bioepis forges licensing deal with Chinese private e…
  • .Samsung Bioepis wins U.S. approval to sell cancer-treating biosimilar .
    Samsung Bioepis wins U.S. approval to sell cancer-treating b…
  • .Samsung Bioepis partners with 3SBio to commercialize biosimilar candidates in China.
    Samsung Bioepis partners with 3SBio to commercialize biosimi…
  • .Celltrion at center of debate over inter-affiliate trading of domestic market rights.
    Celltrion at center of debate over inter-affiliate trading o…
  • .Celltrions biosimilar Remsima reborn as subcutaneous injection.
    Celltrion's biosimilar Remsima reborn as subcutaneous inject…

Real Time Photo News

  • .SM Entertainment agrees to set up joint venture with Indonesian media company.

    SM Entertainment agrees to set up joint venture with Indonesian media company

  • .Girl band AOAs Seolhyun stars in cable TVs historical period drama .

    Girl band AOA's Seolhyun stars in cable TV's historical period drama

  • .BTS becomes first K-pop band to go on global stadium tour.

    BTS becomes first K-pop band to go on global stadium tour

  • .Rookie girl band ITZY drops dance practice video for debut song.

    Rookie girl band ITZY drops dance practice video for debut song

  • .S.E.S. member Shoo gets suspended jail term for habitual gambling.

    S.E.S. member Shoo gets suspended jail term for habitual gambling

Latest News

more+

  • SK Telecom's broadband subsidiary agrees to acquire cable TV operator
  • SM Entertainment agrees to set up joint venture with Indonesian media company
  • LGU+ to demonstrate 5G smart factory solutions at MWC in Barcelona
  • SK hynix selects place to build world's biggest microchip cluster
  • Samsung's foldable phone demonstrates new technology in display
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view